North and Central Texas Clinical and Translational Science Initiative (UL1)

德克萨斯州北部和中部临床和转化科学计划 (UL1)

• 批准号: 7497153
• 负责人: Milton Packer
• 金额: $ 541.63万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-17 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7497153
• 关键词: North; Central; Texas; Clinical; Translational

We propose to establish a North and Central Texas Clinical and Translational Science Initiative (NCTCTSI), which will be led by the University of Texas Southwestern Medical School at Dallas and will include many of the nation's leading schools of allopathic and osteopathic medicine, dentistry, nursing, pharmacy, public health, engineering and computer science - which have already formed a highly functional relationship supported by a Roadmap K12 award. We have established a Department of Clinical Sciences, which is supported by faculty from all participating schools and which will serve as the academic home for our CTSA. The Department provides academic appointments to clinical and translational investigators and to faculty whose expertise and research is focused on methodological disciplines common to all clinical research - in order to promote 'multidisciplinary team building and problem solving. The NCTCTSI will build on existing nationally- recognized programs supported by K30, M01 and Roadmap K12 awards and will integrate numerous institutional strengths to offer 12 highly innovative and fully integrated key functions: (1) building a unique academic home for clinical and translational research; (2) transforming a culture: investigator development and recognition; (3) research education, training and career development; (4) biomedical informatics; (5) stimulating novel translational ideas and methodologies; (6) support for pilot and collaborative studies; (7) research study development: design, statistics and ethics; (8) scientific review and evaluation; (9) regulatory knowledge and support; (10) participant and clinical interactions resources; (11) community engagement; and (12) translational technologies and resources. Particular strengths are: (1) a substantial financial commitment of participating institutions to the Initiative; (2) an established academic and cultural home that currently addresses many of the goals of the NIH;(3) > 200 established clinical and translational investigators who will act as faculty and mentors; (4) a highly innovative approach to integrating key functions that will act to create bonds among the members of a multidisciplinary academic community; (5) a large and medically diverse patient base cared for by internationally-renowned hospitals (which are strong supporters of this initiative); (6) > $150 million in annual peer-reviewed grant support for clinical studies; (7) superb infrastructure to support clinical and translational research; and (8) program leadership with the time, experience and commitment to ensure the success of the Initiative. The coordinated synthesis of these strengths will allow the NCTCTSI to improve the health of our community and to contribute to the national CTSA consortium and thus help to identify best practices that will benefit clinical and translational researchthroughout the nation.

我们建议建立德克萨斯州北部和中部的临床和转化科学倡议 （NCTCTSI），该研究将由位于达拉斯的德克萨斯大学西南医学院领导， 将包括许多全国领先的对抗疗法和整骨疗法医学，牙科， 护理、药学、公共卫生、工程和计算机科学--这些学科已经形成了一个 由K12路线图奖支持的高度功能性关系。我们建立了 临床科学系，由所有参与学校的教师支持， 它将成为我们CTSA的学术之家该部门提供学术 任命临床和翻译研究人员和教师的专业知识和研究是 专注于所有临床研究共同的方法学学科-以促进 多学科团队建设和问题解决。NCTCTSI将建立在现有的国家- K30、M01和Roadmap K12奖项支持的公认计划，并将整合众多 提供12项高度创新和全面整合的主要职能：（1）建立一个 临床和转化研究的独特学术家园;（2）转变文化：研究者 发展和认可;（3）研究教育，培训和职业发展;（4） 生物医学信息学;（5）激发新的翻译思想和方法;（6）支持 试点和合作研究;（7）研究开发：设计、统计和伦理;（8） 科学审查和评价;（9）法规知识和支持;（10）参与者和临床 互动资源;（11）社区参与;（12）转化技术， 资源特别的优势是：（1）参与的实质性财政承诺 （2）一个已建立的学术和文化之家，目前解决 NIH的许多目标;（3）> 200名已建立的临床和翻译研究人员，他们将采取行动 作为教师和导师;（4）高度创新的方法来整合关键功能，将采取行动， 在多学科学术团体的成员之间建立联系;（5）一个庞大的， 医疗多样化的患者基础，由国际知名医院（实力雄厚） 支持者）;（6）> 1.5亿美元的年度同行评审拨款支持临床 研究;（7）支持临床和转化研究的一流基础设施;以及（8）计划 我们需要有时间、经验和承诺的领导力，以确保倡议取得成功。的 这些优势的协调综合将使NCTCTSI能够改善我们的健康， 社区，并为国家CTSA联盟做出贡献，从而帮助确定最佳做法 that will benefit受益clinical临床and translational翻译research研究around the nation国家.